Recombinant Plasma Gelsolin Replacement for Arthritis, Inflammation, Trauma and Burns is under clinical development by BioAegis Therapeutics and currently in Phase I for Burns. According to GlobalData, Phase I drugs for Burns have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Recombinant Plasma Gelsolin Replacement for Arthritis, Inflammation, Trauma and Burns’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Recombinant Plasma Gelsolin Replacement for Arthritis, Inflammation, Trauma and Burns overview

Recombinant plasma gelsolin is under development for the treatment of inflammatory arthritis, trauma, burns and other inflammatory disorders. The drug candidate comprises of recombinant endogenous human protein and is a key component of innate immune system. It is administered by topical route. The drug candidate is being developed based on plasma gelsolin technology.

BioAegis Therapeutics overview

BioAegis Therapeutics that involves in developing therapeutics for infectious, inflammatory and degenerative diseases based on the platform of plasma gelsolin. The company is headquartered in North Brunswick, New Jersey, the US.

For a complete picture of Recombinant Plasma Gelsolin Replacement for Arthritis, Inflammation, Trauma and Burns’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.